Open AccessImpact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients
Author(s) -
Cecile Delille Lahiri,
Sijia Tao,
Yong Jiang,
Anandi N. Sheth,
Edward P. Acosta,
Vincent C. Marconi,
Wendy S. Armstrong,
Raymond F. Schinazi,
Aswani Vunnava,
Sara E. Sanford,
Ighovwerha Ofotokun
Publication year - 2015
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000000659
Subject(s) - atazanavir , darunavir , intracellular , protease inhibitor (pharmacology) , reverse transcriptase inhibitor , protease , ritonavir , peripheral blood mononuclear cell , nucleoside reverse transcriptase inhibitor , tenofovir , pharmacology , virology , hiv 1 protease , lopinavir , enzyme inhibitor , chemistry , medicine , enzyme , human immunodeficiency virus (hiv) , viral load , sida , viral disease , biochemistry , antiretroviral therapy , in vitro
Intracellular nucleoside reverse transcriptase inhibitor (NRTI) concentrations are associated with plasma HIV-1 response. Coadministration of protease inhibitors with NRTIs can affect intracellular concentrations due to protease inhibitor inhibition of efflux transporters. Tenofovir-diphosphate (TFV-DP) concentrations within peripheral blood mononuclear cells were compared among individuals receiving either atazanavir or darunavir-based regimens. There was a trend towards higher TFV-DP concentrations among women and among participants receiving atazanavir. TFV-DP intracellular concentrations were positively associated with undetectable plasma HIV-1 RNA.